Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abraham Shashoua

Urogynecology and Reconstructive Pelvic Surgery Chicago, IL Medical Doctor

NPI 1508899311 CMS profile 249674

3000 N Halsted St, Suite 405, Chicago, IL 60657

Open in the dashboard

General payments

$338,934

531 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abraham Shashoua of Chicago, IL is reported in the CMS Open Payments database as having received $338,934 across 531 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,861 57
2024 General $29,356 51
2023 General $17,886 44
2022 General $31,308 60
2021 General $55,086 66
2020 General $52,158 63
2019 General $142,280 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abraham Shashoua
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Abraham Shashoua were reported at $10,861. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Abraham Shashoua Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $142,280 $358 $132–$1,270 $163
2020 $52,158 $198 $86–$642 $114
2021 $55,086 $361 $118–$1,182 $132
2022 $31,308 $410 $128–$1,175 $149
2023 $17,886 $434 $152–$1,344 $160
2024 $29,356 $494 $193–$1,331 $164
2025 $10,861 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $240,182 263 payments
  2. Gynesonics, Inc. $46,186 61 payments
  3. Acessa Health Inc. $29,226 38 payments
  4. Sumitomo Pharma America, Inc. $4,809 36 payments
  5. Acessa Health Inc. $4,317 5 payments
  6. Myovant Sciences Inc. $4,117 10 payments
  7. Allotrope Medical, Inc $2,968 4 payments
  8. Boston Scientific Corporation $2,765 42 payments
  9. Hologic, LLC $812 9 payments
  10. Medtronic, Inc. $634 17 payments
  11. Other $2,919 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $219,870 93 payments
  2. Consulting Fee $90,543 36 payments
  3. Food and Beverage $18,432 328 payments
  4. Travel and Lodging $9,921 67 payments
  5. Education $168 7 payments
Products named General payments · program years 2019–2025
  1. Orilissa Endocrinology $107,398 115 payments
  2. ORILISSA Womens Health $76,107 82 payments
  3. ORIAHNN $71,289 72 payments
  4. SONATA SONOGRAPHY-GUIDED TRANSCERVICAL FIBROID ABLATION SYSTEM Sonata Transcervical Fibroid Ablation System $40,093 56 payments
  5. Acessa $29,226 38 payments
  6. MYFEMBREE $8,443 34 payments
  7. Sonata Sonography-Guided Transcervical Fibroid Ablation System Surgical $6,639 11 payments
  8. ACESSA PROVU SYSTEM $4,466 7 payments
  9. StimSite $2,637 2 payments
  10. BOTOX $536 19 payments
  11. Other $8,241 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

204

Median for Obstetrics & Gynecology: 65

Drug cost

$46,603

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

43.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 40 $37,835
Solifenacin Succinate Generic 93 $5,541
Estradiol Generic 23 $2,521
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 15 $424
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $152
Oxybutynin Chloride Er Oxybutynin Chloride Brand 18 $131

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$35,711

Medicare's payments for the services billed

Medicare patients

80

Average age 68

Services billed

803

80 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 54%
Diabetes 33%
Depression 33%
Osteoporosis 28%
Ischemic heart disease 23%
Chronic kidney disease 19%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $223
$223 — —
BOTOX
  • AbbVie, Inc. $182
$182 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

531 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record